Biotech3 months ago
Valneva Partners with LimmaTech to Accelerate Shigellosis Vaccine Development
Valneva has partnered with LimmaTech Biologics to acquire exclusive rights to develop and market Shigella4V, a vaccine candidate against shigellosis. The agreement includes an upfront payment...